share_log

BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Maintains $15 Price Target

Moomoo 24/7 ·  Apr 1 12:25

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment